The ASCME trial is a multi-centre, randomized double blind (lisdexamfetamine-01 component), open label (Contingency Management component), dose-ascending, placebo controlled trial. Participants will be enrolled in one of the 4 treatment arms:~Arm 1: treatment as usual plus placebo Arm 2: treatment as usual plus placebo and contingency management Arm 3: treatment as usual plus lisdexamfetamine (LDX-01) Arm 4: treatment as usual plus lisdexamfetamine (LDX-01) and contingency management~The trial will enroll 440 participants, and will be conducted in 5-7 treatment centres across Canada.~Participants will be enrolled in the trial for 20 weeks altogether.
The goal of this clinical trial is to learn if administering a high dose stimulant with Contingency Management reduces days of use in adults who use methamphetamine better than the usual treatment provided by the clinic.~The main questions the trial aims to answer are:~Is a high dose stimulant better than a placebo and usual treatment at helping reduce the number of days they use methamphetamine? Is a high dose stimulant with contingency management better than placebo and usual treatment at helping people reduce the number of days they use methamphetamine?~Participants will be placed randomly into one of four groups:~Usual treatment and placebo~Usual treatment, placebo and contingency management~Usual treatment and high dose stimulant~Usual treatment, high dose stimulant and contingency management~Participation includes the following:~Participants will receive medication or placebo weekly for 15 weeks.~Participants will attend the clinic for weekly treatment~Participants will attend the clinic once every 2 weeks for study visits. Each visit will take about an hour to complete. At these visits, participants will be asked to provide a urine sample and complete questionnaires.